Jana Onda, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 434 Sycamore Ln, Lowell, IN 46356 Phone: 219-741-0756 Fax: 219-595-0047 |
Mrs. Kelly Ann Calvillo, MHS Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 2254 Spring Run Ln, Lowell, IN 46356 Phone: 708-426-3033 Fax: 219-690-3119 |
Talk Time Speech Therapy, Inc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 534 Walnut Ln, Lowell, IN 46356 Phone: 219-696-6432 Fax: 219-696-6432 |
Jane Brady, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 534 Walnut Ln, Lowell, IN 46356 Phone: 219-696-6432 Fax: 219-696-6432 |
Mrs. Nanette Marie Witt, MHS-CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17274 White Oak Ave, Lowell, IN 46356 Phone: 219-690-1051 |
News Archive
"A new aid landscape is emerging that increasingly involves a smaller role for traditional donors like the U.S. government and the World Bank,"
The Associated Press further analyzed its poll from earlier this week, with an eye on medical malpractice limits: "54 percent favor making it harder to sue doctors and hospitals for mistakes taking care of patients, while 32 percent are opposed. The rest are undecided or don't know. But congressional Democrats are reluctant to press forward on the issue. They don't want to upset a valuable political constituency — trial lawyers — even if President Barack Obama says he believes that fear of being sued leads doctors to practice defensive medicine, driving up costs for everyone."
Imaging Dynamics Company Ltd. ("IDC" or the "Company") a global supplier in the high growth digital radiography equipment market, announces that it has received a receipt dated August 11, 2010 for a final short form prospectus (the "Prospectus") filed with the securities commission in each of the provinces of Alberta, British Columbia, Manitoba and Ontario, relating to its previously announced rights offering (the "Offering"). The Company is seeking to raise $2,617,443 in gross proceeds from the Offering.
In the most comprehensive study to date, neurologists have clearly identified significant differences in the ways that Alzheimer's disease affects patients with and without the apolipoprotein E ε4 gene, a known genetic risk factor for the neurodegenerative disease, using a combination of cognitive and neuroanatomic measures. The study found that this gene influences the way the disease manifests, even at its mildest clinical stages.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.
› Verified 3 days ago